Navigation Links
Automated, Wearable Kidney Offers Continuous Dialysis
Date:7/26/2008

UCLA team develops device giving patients freedom of movement, better quality of life

SATURDAY, July 26 (HealthDay News) -- An automated artificial kidney that can be worn on the body may one day be to dialysis patients what the insulin pump is to diabetes patients.

The automated, wearable artificial kidney (AWAK) works better than conventional dialysis, according to a paper in the current issue of Clinical and Experimental Nephrology.

"What's really new about it is the patient's freedom," Martin Roberts, co-designer of the device and an assistant professor of clinical medicine at the David Geffen School of Medicine at UCLA and a dialysis consultant with the Veterans Affairs Los Angeles Healthcare system, said in a university news release. "To me, as the inventor, the most important thing for the patients is their freedom. The next important thing is that because it's working all the time instead of intermittently, you can do a much better job of treating the patient. So we expect the patient to feel better and live longer."

UCLA-VA has already signed an exclusive licensing agreement with AWAK Technologies Pte. Ltd., in Singapore, to develop the design.

The AWAK, which is bloodless, improves upon a previous artificial kidney that was portable but not actually wearable. It improves greatly on conventional dialysis, which requires patients to be connected to a machine for hours.

The new machine would function 24/7, as do actual kidneys, so it would present fewer "shocks" to the patient's system.

More information

The National Kidney Foundation has more on dialysis.



-- HealthDay Staff



SOURCE: University of California, Los Angeles, news release, July 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Researchers design model for automated, wearable artificial kidney
2. Quest Diagnostics Chooses Roches Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide
3. Realtime Technologies Launches SHIMMER - a Wearable Health Sensor for Both Connected and Wireless Environments
4. Wearable Artificial Kidney Passes Test
5. Kidney Community Thanks Congress for Passing Landmark End Stage Renal Disease (ESRD) Reform
6. Kidney transplants less successful at night
7. Global Warming Linked to Heightened Kidney Stone Risk
8. Kidney Community Applauds Senate for Passage of End Stage Renal Disease (ESRD) Improvements
9. Male kidneys for men only?
10. Molecule Uses Cellular Recycling to Treat Kidney Cancer
11. Stanford researchers find molecule that kills kidney cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)... NASHVILLE, Tenn., Jan. 7 Ambulatory Services of...outh Alabama, LLC, its seventh,radiation oncology ...enture,among Gulf Coast Cancer Center - Gulf Shore...nd South Alabama Radiation Oncology, P.C., and ASA...ica, Inc. ROSA of South,Alabama will own and oper...
(Date:1/7/2009)...N ANTONIO, Jan. 7 BioMedical Enterprises, Inc. (B... on the development of orthopaedic memory metal im...eth I. Moch as its President and Chief Executive O...ill become Chief Technology Officer and continue t...roduct offerings. , , BME specializes in nitinol...
(Date:1/7/2009)...e lymphoblastic leukemia is most common pediatric ...ws) -- A mutation in leukemia cells predicts which...re likely to relapse. , The discovery, reported on...e , might lead to tests to help physicians fine-tu..."The treatment of acute lymphoblastic leukemia (AL...
(Date:1/7/2009)...cientists have identified mutations in a gene that...with acute lymphoblastic leukemia (ALL). Although ...eeded to determine how changes in the gene, called...ndings are likely to provide the basis for future ...ailure. By using a molecular test to identify thi...
Breaking Medicine News(10 mins):Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Gulf Coast Cancer Centers 2Health News:BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer 2Health News:Gene Governs Response to Leukemia Chemotherapy 2Health News:Gene abnormality found to predict childhood leukemia relapse 2Health News:Gene abnormality found to predict childhood leukemia relapse 3Health News:Gene abnormality found to predict childhood leukemia relapse 4
...sivity symptoms showed dramatic improvements with ...uncil’s senior education psychologist, Dr Madelein...been rated with moderate to severe ADHD and impuls...mega-3 fish and omega-6 evening primrose oil over ...
... of the storm once again, with confirmed cases of ...harashtra. Following the bird-flu notification// i...k of March, samples were sent to High Security Ani... has confirmed that seven samples had tested posit...
...ds, which consists of the some of the earth’s most...al conservation map//, and is said to be the third...tin Puta Tofinga, Minister of Environment, Lands a...ublic of Kiribati, announced the establishment of ...
... jointly by University of California, Berkeley, an...xposed to high levels of arsenic// in drinking wat...ll a victim to other lung diseases later in their ...of dying from bronchiectasis was 46 times more tha...
Other Medicine News:Health News:Phoenix Islands To Be Protected Under Global Conservation Map 2Health News:Phoenix Islands To Be Protected Under Global Conservation Map 3Health News:Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life 2
(Date:1/7/2009)...n. 7 Scientists have id...ikelihood of relapse in children with acute lympho...aution that further research is needed to determin...OS, lead to leukemia relapse, the findings are li...sts to assess the risk of treatment failure. By us...
(Date:1/7/2009)...d, January 7 Circassia Ltd, a spec...y and critical care, today,announced that followi...th,its ToleroMune(R) anti-allergy technology, the...r a further phase II clinical trial in cat allergy...ruited 120 patients with confirmed,cat allergies,...
(Date:1/6/2009)...n. 6 Sequella, Inc., a ...n diseases of epidemic potential, announced today ...ent of tuberculosis (TB), was the first drug appro...gram contract to Dynport Vaccine Company LLC and Q...he National Institute of Allergy and Infectious Di...
(Date:1/5/2009)... Jan. 5 Micromet, Inc.,...eloping novel, proprietary,antibodies for the tre...ases,provides an outlook on key events anticipat...to provide an update on its research and developme...April 12 to 16, 2009: Update on several preclinica...
Breaking Medicine Technology:Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Cardinal Health GE Healthcare Broaden Relationship to Offer Greater Access to Myoview 28TM 29 Imaging Agent 14581 1Cardinal Health GE Healthcare Broaden Relationship to Offer Greater Access to Myoview 28TM 29 Imaging Agent 14581 2Cardinal Health GE Healthcare Broaden Relationship to Offer Greater Access to Myoview 28TM 29 Imaging Agent 14581 3Cardinal Health GE Healthcare Broaden Relationship to Offer Greater Access to Myoview 28TM 29 Imaging Agent 14581 4Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvanias Uninsured 14579 1Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvanias Uninsured 14579 2Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvanias Uninsured 14579 3Transition Therapeutics to Present at Cowen 26 Company 28th Annual Healthcare Conference 14577 1Transition Therapeutics to Present at Cowen 26 Company 28th Annual Healthcare Conference 14577 2C1 Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema According to Pivotal Study 4050 1C1 Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema According to Pivotal Study 4050 2C1 Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema According to Pivotal Study 4050 3C1 Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema According to Pivotal Study 4050 4
...on highlights health care cost benefit of,bioengin...ire-FirstCall/ -- Cell,Therapeutics, Inc. (CTI) an...ting of the American Society of Clinical Oncology ...tilization (MRU) and,associated costs with XYOTAX ...itabine or vinorelbine in treating patients with,n...
...1 Phase III Study Results Presented At ASCO -- , C...tment with,pegylated interferon alfa-2b in stage I... on relapse-free survival (RFS),according to the ...ed in patients with stage III melanoma. Results of...tion for the Research and,Treatment of Cancer (EOR...
Other Medicine Technology:XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine,or Vinorelbine in Treating Non-Small Cell Lung Cancer 2XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine,or Vinorelbine in Treating Non-Small Cell Lung Cancer 3XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine,or Vinorelbine in Treating Non-Small Cell Lung Cancer 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5
Inquire
Adjustable speed vortex with inter-changeable heads, 110 V
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures.
Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr
Medicine Products: